Revised: 24 May 2019

#### **RESEARCH ARTICLE**

### The C-type lectin receptor MGL senses *N*-acetylgalactosamine on the unique *Staphylococcus aureus* ST395 wall teichoic acid

Malgorzata E. Mnich<sup>1,2</sup> | Rob van Dalen<sup>1</sup> | David Gerlach<sup>3,4</sup> | Astrid Hendriks<sup>1,2</sup> | Guoqing Xia<sup>5</sup> | Andreas Peschel<sup>3,4</sup> | Jos A.G. van Strijp<sup>1</sup> | Nina M. van Sorge<sup>1</sup>

<sup>1</sup>Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

<sup>2</sup>Glaxo-Smith Kline, Siena, Italy

<sup>3</sup> Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen, Tübingen, Germany

<sup>4</sup> German Center for Infection Research (DZIF), Tübingen, Germany

<sup>5</sup>Lydia Becker Institute of Immunology and Inflammation, Division of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK

#### Correspondence

Nina M. van Sorge, Medical Microbiology, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands. Email: nsorge3@umcutrecht.nl

Funding information H2020 Marie Skłodowska-Curie Actions, Grant/Award Number: 675106

#### Abstract

Staphylococcus aureus is a common skin commensal but is also associated with various skin and soft tissue pathologies. Upon invasion, S. aureus is detected by resident innate immune cells through pattern-recognition receptors (PRRs), although a comprehensive understanding of the specific molecular interactions is lacking. Recently, we demonstrated that the PRR langerin (CD207) on epidermal Langerhans cells senses the conserved  $\beta$ -1,4-linked N-acetylglucosamine (GlcNAc) modification on S. aureus wall teichoic acid (WTA), thereby increasing skin inflammation. Interestingly, the S. aureus ST395 lineage as well as certain species of coagulase-negative staphylococci (CoNS) produce a structurally different WTA molecule, consisting of poly-glycerolphosphate with  $\alpha$ -O-N-acetylgalactosamine (GalNAc) residues, which are attached by the glycosyltransferase TagN. Here, we demonstrate that S. aureus ST395 strains interact with the human Macrophage galactose-type lectin (MGL; CD301) receptor, which is expressed by dendritic cells and macrophages in the dermis. MGL bound S. aureus ST395 in a tagN- and GalNAc-dependent manner but did not interact with different tagN-positive CoNS species. However, heterologous expression of Staphylococcus lugdunensis tagN in S. aureus conferred phage infection and MGL binding, confirming the role of this CoNS enzyme as GalNAc-transferase. Functionally, the detection of GalNAc on S. aureus ST395 WTA by human monocyte-derived dendritic cells significantly enhanced cytokine production. Together, our findings highlight differential recognition of S. aureus glycoprofiles by specific human innate receptors, which may affect downstream adaptive immune responses and pathogen clearance.

#### KEYWORDS

C-type lectin receptor, innate immunity, microbial-cell interaction, staphylococci, virulence

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2019 The Authors Cellular Microbiology Published by John Wiley & Sons Ltd

### <sup>2 of 10</sup> WILEY

#### 1 | INTRODUCTION

Staphylococcus aureus is a common member of the human microbiome and colonises up to 30% of the population, where it mostly resides in the nares and on the skin (Eriksen, Espersen, Rosdahl, & Jensen, 1995; Kluytmans, van Belkum, & Verbrugh, 1997; Wertheim et al., 2005). *S. aureus* is a leading cause of surgical site infections and skin infections as well as health care-associated pneumonias (Pozzi et al., 2017). Treatment of infections is hampered by the continuous emergence of antimicrobial resistance, most prominently methicillin-resistant *S. aureus* and vancomycin-resistant *S. aureus* (Weigel et al., 2003, Lakhundi & Zhang, 2018). Understanding the molecular mechanisms underlying different *S. aureus* infections will support the development of new treatment strategies including vaccines.

Components of the bacterial cell envelope are critical for S. aureus host-pathogen interaction, both at the level of colonisation but also during systemic infection by evading host immune responses (Weidenmaier & Lee, 2016). One of the most abundant and exposed structures on the Gram-positive cell wall is wall teichoic acid (WTA). WTA is a glycopolymer that is covalently bound to peptidoglycan. WTA is critical for S. aureus physiology and infection biology through its role in cation sequestration, horizontal gene transfer by bacteriophages, and adherence function to human nasal epithelial cells (Weidenmaier & Peschel, 2008, Swoboda, Campbell, Meredith, & Walker, 2010, Winstel et al., 2013). In the majority of S. aureus strains, WTA is composed of a poly-ribitolphosphate (RboP) backbone decorated with positively charged D-alanine and N-acetyl-D-glucosamine (GlcNAc) residues. Synthesis of the WTA RboP backbone and its modification is orchestrated by tar genes. tarM, tarS, and tarP encode specific glycosyltransferases that catalyse the attachment of GlcNAc residues. TarM adds  $\alpha$ -GlcNAc residues at C4 hydroxyl groups of RboP, whereas TarS and TarP modify RboP with β-GlcNAc residues at C4 or C3 hydroxyl groups, respectively (Brown et al., 2012; Gerlach et al., 2018; Xia et al., 2010). The WTA  $\alpha$ - and  $\beta$ -GlcNAc modifications impact interactions of S. aureus with both innate and adaptive immune components, including mannose-binding lectin, langerin, and antibodies (Park et al., 2010; Kurokawa et al., 2013; Lee et al., 2015; Gerlach et al., 2018; van Dalen et al., 2019).

Not all *S. aureus* strains express structurally identical WTA. In contrast to the common RboP-GlcNAc WTA, *S. aureus* isolates of the ST395 lineage produce WTA composed of a poly-glycerolphosphate (GroP) backbone decorated with  $\alpha$ -N-acetyl-D-galactosamine ( $\alpha$ -GalNAc) residues, which are attached by glycosyltransferase TagN (Winstel et al., 2013; Winstel, Sanchez-Carballo, Holst, Xia, & Peschel, 2014). The synthesis of this structurally different WTA impacts recognition and horizontal gene transfer by phages (Winstel et al., 2013; Winstel et al., 2014). Interestingly, GroP-GalNAc WTA is also produced by several coagulase-negative staphylococci (CoNS), which are also common inhabitants of skin but are generally less associate with skin pathologies compared with *S. aureus* (Endl, Seidl, Fiedler, & Schleifer, 1983; Winstel et al., 2013; Winstel et al., 2014).

C-type lectin receptors (CLRs) are a family of pattern-recognition receptors that are dedicated to sense both self and non-self glycan

structures through their characteristic carbohydrate recognition domains (CRDs; Brown, Willment, & Whitehead, 2018). CLRs have a particular expression pattern on subsets of immune cells. We recently identified that the CLR langerin (CD207), which is exclusively expressed on Langerhans cells in the skin epidermis, interacts with S. aureus through WTA β-1,4-GlcNAc, which affects Langerhans cell responses and skin inflammation in mice (van Dalen et al., 2019). In contrast, S. aureus ST395 does not interact with langerin (van Dalen et al., 2019). However, both dermal dendritic cells (DCs) and dermal macrophages express the trimeric CLR macrophage galactose-type lectin (MGL; CD301), which recognises terminal GalNAc residues as a result of a Gln-Pro-Asp motif in its CRD (Tanaka et al., 2017). GalNAc is incorporated into, among others, pathogen-produced lipooligosaccharides from Campylobacter jejuni and Neisseria gonorrhoeae (van Sorge et al., 2009; van Vliet et al., 2009), and confers binding to MGL in a Ca<sup>2+</sup>-dependent manner, inducing uptake and cellular responses (van Liempt et al., 2007). We therefore hypothesised that S. aureus ST395 might also be recognised by MGL via α-GalNAc modifications on WTA and may impact downstream immune responses.

Using recombinant MGL constructs, we demonstrate that human MGL and mouse MGL2 interact with *S. aureus* ST395 WTA in a  $\alpha$ -GalNAc- and *tagN*-dependent manner. Interestingly, *tagN*-encoding CoNS did not interact with MGL, although heterologous expression in a *tagN*-deficient *S. aureus* background proves their function as GalNAc transferases. Importantly, loss of *tagN* in *S. aureus* ST395 attenuates production of specific cytokines by human monocyte-derived dendritic cells (moDCs).

#### 2 | RESULTS

## 2.1 | Human MGL interacts with *S. aureus* ST395 strains in a *tagN*-dependent manner

Human MGL is the only CLR family member with specificity for α-GalNAc (van Vliet et al., 2005). Because the S. aureus ST395 lineage produces GalNAc-decorated WTA, we investigated whether S. aureus ST395 was recognised by human MGL. Using flow cytometry, we tested multiple S. aureus isolates from the ST395 lineage for binding to recombinant soluble his-tagged MGL. All strains of this lineage bound MGL, whereas no interaction was observed with USA300 and Newman strains (non-ST395 strains), which both express RboP-GlcNAc WTA (Figure 1a). Interestingly, the levels of MGL binding varied for different ST395 strains (Figure 1a), likely reflecting different expression levels of the MGL ligand. Addition of soluble GalNAc prevented interaction of MGL with ST395 strain PS187, whereas similar levels of glucose did not affect binding (Figure 1b), indicating that binding occurs through the MGL CRD. To confirm that the interaction between S. aureus ST395 and MGL depends on WTA GalNAc, we assessed binding of MGL to wild-type (WT) PS187 and the isogenic mutant strain GN1, which lacks the C-terminal glycosyltransferase domain of tagN and is consequently deficient for WTA α-GalNAc (Winstel et al., 2014). MGL binding was lost in the tagN-



**FIGURE 1** Human and mouse macrophage galactose-type lectin (MGL) interact with *Staphylococcus aureus* ST395 strains in a *tagN*-dependent manner. (a) hMGL binding to different S. *aureus* ST395 lineage strains, USA300 wild-type (WT) and Newman WT detected by anti-hisTag-FITC antibody. Control represents S. *aureus* PS187 WT incubated with secondary detection antibody. (b and d) Interaction between (b) hMGL or (d) mMGL2 to S. *aureus* PS187 WT in the absence or presence of GalNAc (50 mM) or glucose (50 mM). (c and e) Binding of (c) hMGL or (e) mMGL2 to PS187 WT, GN1, GN1 + *ptagN* and two non-ST395 strains. Means of geometric mean fluorescence intensity ± standard error of mean from three independent experiments are shown. \**p* < .05, \*\**p* < .005, \*\*\*\**p* < .0001

deficient mutant and could be restored by complementation with plasmid-expressed full-length *tagN* (Figure 1c), confirming that WTA  $\alpha$ -GalNAc of *S. aureus* ST395 is the ligand of MGL.

We have previously observed that langerin shows a certain level of species specificity, that is, mouse langerin does not interact with *S. aureus* (van Dalen et al., 2019). Therefore, we investigated

### 4 of 10 WILEY

interaction of PS187 with mouse homologue MGL2 (Singh et al., 2009). Like human MGL, mouse MGL2 interacted with PS187, could be blocked with GalNAc, and interaction was lost upon deletion of *tagN* (Figure 1d,e), suggesting that the interaction is, at least partially, conserved across species.

## 2.2 | S. lugdunensis tagN encodes a GalNAc-transferase that produces a MGL ligand

Similar to S. aureus ST395 WTA, certain CoNS species express GroPtype WTA. In addition, several CoNS species express homologues of the tagN gene, suggesting that CoNS may decorate WTA in a similar fashion as S. aureus ST395 strains (Winstel et al., 2014). Indeed, complementation of PS187 GN1 with a tagN homologue from Staphylococcus carnosus restores GalNAc glycosylation and phage susceptibility (Winstel et al., 2014). Similarly, we were able to confer susceptibility to phage  $\phi$ 187 by complementing the GN1 mutant, for which no transductants were obtained, with tagN from Staphylococcus lugdunensis (Figure 2a). In addition, the WTA migration of this complemented strain was similar to that of WTA from PS187 WT (Figure 2b). Importantly, heterologous expression of S. lugdunensis tagN in PS187 GN1 also restored binding to MGL (Figure 2c). In contrast, none of the CoNS species that contain a tagN homologue interacted with MGL (Figure 2 d), despite reactivity with the GalNAc-specific plant lectin SBA for Staphylococcus carnosus, Staphylococcus capitis, and Staphylococcus saprophyticus (Figure S1). These data suggest that S. lugdunensis tagN encodes a GalNAc transferase. However, it is likely not or only lowly expressed in S. lugdunensis in our culture conditions.

## 2.3 | *S. aureus* PS187 interacts with and activates human moDCs

MGL is expressed on a range of immune cells including human DCs and macrophages residing in skin and lymph nodes, blood CD1c + DCs. and immature moDCs (van Vliet, Gringhuis, Geiitenbeek, & van Kooyk, 2006, Schutz & Hackstein, 2014, Heger et al., 2018). To investigate the interaction of MGL with S. aureus ST395 strains in a more biologically relevant system, we used a cell-based assay with human immature moDCs. Fluorescein isothiocyanate (FITC)-labeled S. aureus PS187 WT bound readily and in a ratio-dependent manner to moDCs (Figure 3a,b). Interestingly, binding was reduced for the *tagN*-deficient mutant and USA300 strains, which both do not express GalNAc on their surface (Figure 3b). Binding to moDCs was restored to WT levels in the tagN-complemented strain (Figure 3b). Complementary, we assessed the effect of different blocking agents, that is, ethylene glycol-bis(βaminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), GalNAc, and glucose (as a control; Figure 3c). Binding of PS187 WT, but not of the GN1 mutant, was reduced upon coincubation of EGTA and GalNAc, but not glucose (Figure 3c). These data demonstrate that the PS187moDC interaction is partially preventable by addition of GalNAc or calcium scavenging, which is in line with a possible role for MGL.

Loss of interaction with MGL may affect immune activation of moDCs, such as expression of costimulatory molecules or cytokine

production, resulting in different immunological responses. We therefore investigated moDCs maturation and cytokine production after stimulation with gamma-irradiated S. aureus PS187 WT, GN1, tagNcomplemented GN1, or USA300 WT for 16 hr. MoDCs upregulated maturation markers CD80, CD83, CD86, and CD40, indicating that all S. aureus strains activate moDCs (Figure 4a, Figure S2). We observed little effect on expression of HLA-DR except with PS187 WT (Figure S2). However, there was no difference in the induction of moDC maturation by the different S. aureus strains (Figure 4a, Figure S2). We also analysed moDC cytokine production. S. aureus PS187 WT induced expression of IL-6, IL-12p70, IL23p19, IL-10, and TNFa, but not IL-4 when incubated with moDCs (Figure 4b). Interestingly, at a cell-to-bacteria ratio of 1:2, cytokine production was significantly lower when strains did not produce GalNAcylated WTA, that is, PS187 GN1 and USA300 WT (Figure 4c). At higher ratios, this difference was robust for IL-6 and IL12p70 and trends remained for IL-10, IL23p19, and TNFa (Figure 4c). Cytokine production by moDCs was restored to PS187 WT levels in cells stimulated with the tagNcomplemented strain (Figure 4c). Overall, these data indicate that the production of select pro-inflammatory cytokines, that is, IL-6 and IL12p70, by moDCs is enhanced by recognition of the  $\alpha$ -GalNAc modifications present on S. aureus PS187 WTA.

To determine whether differences in cytokine production are not just WTA GalNAc-dependent but also MGL-dependent, we attempted to block the interaction using a commercially available anti-MGL blocking antibody. These experiments are technically complicated by the presence of protein A and Sbi on the *S. aureus* surface, as these proteins bind IgG Fc, thereby possibly increasing DC interaction by binding to the blocking antibody. MoDC cytokine production in response to PS187 WT was not affected by the presence of either the blocking antibody or the isotype control antibody compared with bacteria alone (Figure S3). We confirmed that incubation of the anti-bodies with moDCs by itself did also not significantly affect cytokine production (Figure S4). Therefore, we are currently unable to prove that moDC cytokine production in response to *S. aureus* PS187 occurs through MGL.

#### 3 | DISCUSSION

Here, we show the molecular interaction between WTA of *S. aureus* ST395 and MGL, an innate receptor of the CLR family. This interaction is dependent on  $\alpha$ -GalNAc modifications of *S. aureus* WTA and contributes to increased cytokine production in MGL-expressing moDCs. Although Winstel et al. showed the importance of *S. aureus* GalNAc glycosylation for phage infection (Winstel et al., 2014), there was no previous indication for interaction with human receptors. Because the ST395 lineage is present in nasal and blood culture isolates (Holtfreter et al., 2007), interaction with MGL may be biologically relevant in context of recognition and clearance by the immune system.

This is the first identification of MGL interaction with a Gram-positive bacterium. Previous studies have identified MGL ligands on the surface of Gram-negative pathogens, including *C. jejuni*,



**FIGURE 2** *Staphylococcus lugdunensis tagN* encodes a GalNAc-transferase that produces a macrophage galactose-type lectin (MGL) ligand. (a) Transfer of SaPI BovI via phage  $\phi$ 187 into PS187 wild-type (WT), GN1 mutant, and GN1 complemented with *tagN* from *S. lugdunensis* (*pSlug tagN*). Values are displayed as transductants per plaque-forming units (TrU/PFU). In case of GN1 no transductants were obtained. (b) PAGE analysis of wall teichoic acid from *Staphylococcus aureus* PS187 WT, GN1 mutant, and GN1 complemented with *tagN* from *S. lugdunensis* (*pSlug tagN*). (c) Binding of hMGL to *S. aureus* PS187 WT, GN1 mutant, and GN1 complemented with *either* PS187 *tagN* (*ptagN*) or *pSlug tagN*. (d) Interaction of different coagulase-negative staphylococci species with hMGL. Means of geometric mean fluorescence intensity ± standard error of mean from three independent experiments are shown. \*\*\*\*p < .0001

*N. gonorrhoeae*, and *Escherichia coli* strain R1 (Maalej et al., 2019; van Sorge et al., 2009; van Vliet et al., 2009). For *Escherichia coli* strain R1, soluble lipo-oligosaccharide (LOS) was identified as a ligand for recombinant human MGL, although no functional consequences were assessed (Maalej et al., 2019). For *C. jejuni*, MGL ligands are GalNAc residues incorporated in LOS and *N*-glycosylated proteins (van Sorge et al., 2009). For *N. gonorrhoeae*, the ligand is a terminal GalNAc residue on the LOS of phenotype C strains, which influenced binding to moDCs and subsequent T helper differentiation (van Vliet et al., 2009). Similarly, our data show that loss of GalNAc on the *S. aureus* surface decreases binding to moDCs, which corresponds with assays

using recombinant MGL. Importantly, binding of GN1 to moDCs could be restored by *tagN* complementation, suggesting that one of the involved receptors is MGL. Experiments using the calcium chelator EGTA and GalNAc monosaccharide also decreased moDC binding, although GalNAc had only a modest inhibiting effect. This may implicate the involvement of other calcium-dependent, GalNAcindependent receptors in the interaction between *S. aureus* PS187 and DCs.

Presence of the GalNAc-WTA epitope also affected DC cytokine production, especially increasing production of IL-6 and IL-12p70 across the tested range of bacteria-to-cell ratios. This is in contrast



**FIGURE 3** Wall teichoic acid-GalNAc contributes to interaction between human monocyte-derived dendritic cells (moDCs) and *Staphylococcus aureus* PS187. (a) Binding of FITC-labeled *S. aureus* PS187 WT (green) to immature moDCs (membrane in red, nucleus in blue). Cytospin samples were prepared from cell suspensions incubated with bacteria in 1:50 ratio for 30 min. (b) Binding of FITC-labeled *S. aureus* strains to moDCs at different cell-to-bacteria ratios after 30 min of incubation. Data are presented as mean ± standard error of mean (SEM) of percentage of FITC-positive moDCs (n = 3). Significance shown as compared with binding of PS187 WT to moDCs within certain ratio in red for dGN1 mutant and in blue for UAS300 WT. (c) Binding of FITC-labeled *S. aureus* PS187 WT and GN1 to moDCs in 1:10 cell-to-bacteria ratio after 30 min in the absence or presence of 1 mM EGTA, 50 mM GalNAc or 50 mM glucose (control). Data are presented as a mean ± SEM of percentage of FITC-positive moDCs (n = 3). \*p < .05, \*\*p < .01, \*\*\*p < .005

to observations with C. jejuni, where absence of the MGL ligand on glycosylated proteins actually increased DC cytokine production, suggesting that MGL triggering dampened immune activation. These contrasting outcomes suggest that the context in which MGL is engaged influences how MGL affects DC responses. Indeed, previous reports have indicated that MGL triggering alone does not induce high cytokine secretion by CD1c + DCs but requires costimulation with Toll-like receptor ligands to differentially affect IL-8, IL-10, and TNFa production (Heger et al., 2018; van Vliet et al., 2013). Because Toll-like receptor ligands differ between Gram-positive and Gram-negative bacteria, this may explain the different effects on DC cytokine production that we observe here. Alternatively, we can speculate that observed differences in DC cytokine production are not completely MGL-dependent. It cannot be excluded that additional receptors were triggered in the absence of WTA-GalNAc as a result of newly exposed structures on the S. aureus surface. Additionally, other receptors may be more important for induction of cytokines, which is also implied by the experiments using anti-MGL blocking antibodies, which did not affect cytokine production.

It has been well established that MGL binds to galactose- and GalNAc-rich terminal motifs in a Ca<sup>2+</sup>-dependent manner (Suzuki, Yamamoto, Toyoshima, Osawa, & Irimura, 1996; van Vliet et al., 2005). These modifications are often found in the extracellular matrix of host tissues. Interaction of DCs with extracellular matrix via MGL inhibits their migration from dermis to the lymph nodes. Therefore, the presence of MGL-expressing DCs in the skin might be explained by the abundance of GalNAc epitopes in dermal tissues (van Vliet, Paessens, Broks-van den Berg, Geijtenbeek, & van Kooyk, 2008). Recognition of GalNAc-decorated bacteria, such as S. aureus PS187, by dermal DCs can disrupt the interaction with the extracellular matrix, which consequently would allow DCs to migrate to the lymph nodes to present antigen. In addition, the observation that the detection of GalNAc-epitopes enhances cytokine production additionally suggests that this interaction is an immune defense strategy and likely not a part of the immune evasion repertoire of S. aureus.

When dermal DCs encounter pathogens and migrate to the lymph nodes to present antigens, the final step is to develop an adaptive immune response to eradicate these pathogens. Previous studies have demonstrated high levels of IgG antibodies against WTA GlcNAc modifications in human serum, indicating the importance of this epitope in adaptive immunity. Specifically, the anti-WTA  $\beta$ -1,4-GlcNAc antibodies induce complement activation and opsonophagocytosis of *S. aureus* strains expressing a RboP-GlcNAc WTA (Lee et al., 2015). Because *S. aureus* ST395 expresses an alternative WTA structure with a different glycosylation pattern, it will be of interest to study whether antibody responses are mounted against this specific WTA glycoepitope and whether these antibodies facilitate *S. aureus* phagocytosis and killing.

Surprisingly, our data did not show any binding of MGL to CoNS. This could simply reflect lack of *tagN* gene expression under the tested growth conditions. Alternatively, it may indicate that additional factors such as epitope density, capsule expression or overall accessibility prevent MGL interaction, which are potentially different in *S. lugdunensis* compared with *S. aureus*. The observation that heterologous expression under a constitutive promoter confers both susceptibility to phage  $\phi$ 187 as well as MGL binding does not exclude either possibilities, but does confirm that *tagN* from *S. lugdunensis* encodes an  $\alpha$ -GalNAc transferase. The observed discrepancy between SBA and MGL binding to several CoNS suggests that, despite high homology between *S. aureus* and CoNS *tagN* genes, the pattern or specificity of WTA GalNAc decoration may be slightly different, thereby preventing interaction for MGL.

In summary, we have demonstrated that *S. aureus* ST395 lineages engage the receptor MGL and induce maturation and cytokine production of human DCs, which is partially dependent on expression of WTA-GalNAc. Together with the previous findings that RboP-GlcNAc interacts with langerin, these findings create an overall view that the *S. aureus* WTA glycosylation profile dictates the interaction with specific innate immune receptors on antigen-presenting cells, which may have important consequences for immune defense and pathogen clearance.



**FIGURE 4** Human monocyte-derived dendritic cells (moDCs) are activated by *Staphylococcus aureus* PS187 and cytokine production is affected by wall teichoic acid-GalNAc. (A) Relative expression of surface maturation markers on moDCs after stimulation with gamma-irradiated *S. aureus* strains at cell-to-bacteria ratio of 1:10 for 16 hr. Data are presented as fold change  $\pm$  standard error of mean (SEM) relative to unstimulated control (n = 3 donors). (B) Cytokine expression by moDCs after 16 hr of incubation without or with gamma-irradiated *S. aureus* PS187 WT in 1:10 cell-to-bacteria ratio. Data are presented as mean of cytokine concentration  $\pm$  SEM (n = 6 donors). (C) Cytokine expression by moDC after incubation with gamma-irradiated *S. aureus* strains in 1:2, 1:5, and 1:10 cell-to-bacteria ratio for 16 hr. Data are presented as mean of fold increase over PS187 WT 1:2  $\pm$  SEM (n = 6 donors). \*p < .05, \*\*p < .05, \*\*\*p < .005, \*\*\*\*p < .0001

#### 4 | EXPERIMENTAL PROCEDURES

#### 4.1 | Bacterial strains

Bacteria (Table S1) were grown either on Todd Hewitt (Oxoid) agar or in Todd Hewitt broth supplemented with chloramphenicol (Sigma-Aldrich) at a concentration 10  $\mu$ g/ml when required. For all experiments, bacteria were grown overnight, subcultured the next day in

fresh Todd Hewitt broth, and grown to exponential phase (optical density at 600 nm  $[OD_{600}]$  = 0.6) for use in experiments.

7 of 10

#### 4.2 | Molecular cloning

*TagN* was amplified using primer pair N474-slug-bam (up; 5'-ATCG-GATCCAAAGGAGGTATTATAATGGCATTAAAGAAATTTATAATTAA-TCA-3') and N474-slug-Eco(dn;5'-GAGAGAATTCCTATTTAAGTAGC

TTATAAAATTCATTA-3') and genomic DNA of *S. lugdunensis* HKU09-01 as template. The amplicon was cloned into shuttle-vector pRB474 (Bruckner, 1992) via the BamHI and EcoRI restriction sides.

#### 4.3 | SaPI transfer assay

Lysate of SaPlbov1 ( $\phi$ 187) bearing a tetracyclin resistance marker was generated as previously described (Winstel et al., 2014). In brief, overnight culture of PS187 SaPlbov1::tet (final OD 0.1) of was incubated with  $\phi$ 187 (final concentration of  $10^7$  plaque forming units (PFU)/mL) in a final volume of 10 mL TSB for 30 min at 37°C and subsequently at 30°C until visible bacterial lysis. The obtained lysate was centrifuged and filtered (pore size 0.2-0.45 µm). SaPl transfer was performed by mixing 100 µL of SaPl lysate with 200 µL of stationary bacteria (OD = 0.5) and subsequent incubation for 15 min at 37°C. The mixture was centrifuged for 3 min at 10,000 g and plated on Tryptic soy agar (TSA) plates supplemented with 3 µg/mL tetracycline. Plates were incubated overnight at 37°C, and transductants were enumerated.

## 4.4 | WTA isolation and analysis by polyacrylamide gel electrophoresis (PAGE)

WTA was isolated as previously described (Winstel et al., 2013). Briefly, overnight culture of *S. aureus* PS187 was grown in BM (0.5 % w/v yeast extract; 1% w/v Soy peptone; 0.5% NaCl; 0.1 % K2HPO3) supplemented with 0.25% w/v glucose was harvested by centrifugation and washed using ammonium acetate buffer (AAB, 20 mM, pH 4.8). Bacterial cells were opened using a Euler cell mill (2.5 mL AAB/4.5 glass beads/1 g cell pellet). The obtained lysate was digested overnight with RNAse and DNAse at 37°C, subsequently treated by ultrasonification, and incubated with 2% sodium dodecyl sulfate (SDS) for 1 hr at 60°C. Purified peptidoglycan was washed extensively with AAB. WTA was released by 5% tri chloroacetic acid (TCA) treatment for 4 hr at 60°C. The supernatant was neutralised using NaOH and dialyzed against ddH2O.

PAGE analysis of WTA occurred as previously described (Xia et al., 2010). WTA samples (400 nmol phosphate) were applied to a polyacrylamide gel (26%) and separated electrophoretically for 13 hr at 25 mA. WTA bands were visualised using Alcian blue (0.005%) in staining solution (40% ethanol, 5% acetic acid).

#### 4.5 | Lectin binding assay

Bacteria were harvested by centrifugation (4,000×g, 10 min) and resuspended to OD<sub>600</sub> of 0.4 in Tris buffer (20 mM Tris [Roche], 150 mM NaCl [Sigma-Aldrich], 2 mM CaCl<sub>2</sub>·2 H<sub>2</sub>O [Merck], 2 mM MgCl<sub>2</sub>·6 H<sub>2</sub>O [Merck], pH 7.0; TSM) with 0.1% bovine serum albumin (BSA, Merck). Bacteria were incubated with 5 µg/ml of recombinant human MGL-his (R&D Systems), 10 µg/ml of recombinant mouse MGL2-his (R&D Systems), 4 µg/ml of SBA-FITC (soy bean agglutinin, Vector Laboratories), or 2 µg/ml of sWGA-FITC (succinylated wheat germ agglutinin, Vector Laboratories). Binding of recombinant human MGL and murine MGL2 was detected using anti-hisTag FITC-conjugated antibodies (LifeSpan BioSciences). For blocking, we used soluble *N*-acetyl-D-galactosamine (Fluka, Sigma-Aldrich) or glucose (Merck) at 50 mM. Samples were analysed using flow cytometry (FacsVerse, BD Biosciences).

## 4.6 | Isolation of human monocytes and differentiation to immature DCs

Buffy coats from healthy anonymous donors were purchased from Sanguin Amsterdam and obtained according to the good clinical practice in accordance with the declaration of Helsinki. Donors have given their written consent to the study. Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats using Ficoll-Pague PLUS (GE Healthcare) density gradient and monocytes were obtained as described in Sallusto and Lanzavecchia (1994). Briefly, harvested PBMCs were washed twice with RPMI 1640 (Lonza) supplemented with 5% foetal bovine serum (FBS, Biowest). Monocytes were further isolated from the PBMC fraction using density gradient of 60%, 47.5 %, and 34 % Percoll (Sigma-Aldrich) in RPMI 1640 + 10% FBS. Harvested monocytes were washed three times with RPMI 1640 + 5% FBS and incubated at the concentration  $0.5 \times 10^6$  cells/ml with differentiation medium consisting of RPMI 1640 supplemented with 10% HyClone FBS (GE Healthcare), 800 IU/ml GM-CSF (Bio Connect), 250 IU/ml IL-4 (Thermo Fisher Scientific), 100 IU/ml penicillin-streptomycin, and 2.4 mM L-glutamine for 5 to 7 days to obtain immature DCs.

#### 4.7 | Binding of FITC-labeled bacteria to moDCs

To perform bacteria binding assays, *S. aureus* strains were labelled with FITC (Sigma-Aldrich). Five milligrams of bacterial culture in exponential phase were pelleted and resuspended in cold PBS with 0.1% BSA. Bacteria were incubated with 0.5 mg/ml FITC for 30 min on ice protected from light. Bacteria were washed three times with cold PBS + 0.1% BSA supplemented with 1% ammonia and resuspended in TSM + 0.1% BSA at  $OD_{600}$  of 0.4.

Immature moDCs were harvested by centrifugation and resuspended in TSM + 0.1% BSA ( $1 \times 10^6$  cells/ml). Cells were incubated with bacteria at 1:2, 1:5, 1:10, and 1:20 cell to-bacteria ratios in a 96-well round bottom plate for 30 min in 4°C protected from light. For blocking, cells were preincubated for 15 min at room temperature with 1 mM EGTA (Brunschwig Chemie), 50 mM GalNAc (Fluka, Sigma-Aldrich), or 50 mM glucose (Merck). Next, cells were incubated with bacteria at 1:10 cell-to-bacteria ratio for 30 min at 4°C, protected from light. Samples were washed with TSM + 1% BSA, fixed using 1% formaldehyde in PBS, and analysed using flow cytometry. Microscopy pictures were prepared using 1:50 cell to bacteria ratio suspensions. Cells were attached to the glass slides using a Shandon Cytospin 3 centrifuge. Cellular membranes were stained using WGA-Alexa Fluor 647 (Thermo Fisher Scientific), cell nucleus with DAPI (Sigma-Aldrich). Samples were fixed with 1% formaldehyde (Merck) in PBS (Lonza), and cover slides were attached with mounting medium. Samples were analysed using confocal laser scanning microscopy (SP5, Leica).

# 4.8 | Stimulation of moDCs with gamma-irradiated bacteria

*S. aureus* strains at exponential growth phase were washed with PBS and resuspended in PBS with addition of glycerol. Gamma irradiation of bacteria was performed by Synergy Health Ede B.V., a STERIS company (Ede, The Netherlands), and loss of viability was verified by culture. Concentrations of all bacterial suspensions were measured using MACSQuant Analyzer 10.

Immature moDCs were harvested, washed, and resuspended in RPMI +5% FBS. Before use, cells were stained for expression of MGL and maturation markers using MGL-PE, CD80-PE, CD83-APC, CD86-APC (all SONY Biotechnology), CD40-FITC, and HLA-DR-APC (both BD Biosciences) antibodies and their corresponding isotype controls (BD Biosciences), diluted according to the manufacturers' instructions. Samples were analysed using flow cytometry. Bacteria were diluted in RPMI +5% FBS and mixed with  $0.5 \times 10^5$ immature moDCs in 1:2, 1:5, and 1:10 cell-to-bacteria ratios. Suspensions were incubated in Corning 96-well round bottom ultra-low attachment plates (Sigma-Aldrich) for 16 hr at 37°C with 5% CO<sub>2</sub>. For blocking, moDCs were incubated for 16 hr with S. aureus PS187 WT at 1:2, 1:5, and 1:10 cell-to-bacteria ratios in the presence of anti-MGL blocking antibodies (ASGPR/MGL, clone 125A10.03, Dendritics) or isotype control antibodies (produced and purified in-house) at the concentration 10 µg/ml. Supernatants were collected after centrifugation, and cells from 1:10 cell-to-bacteria conditions were stained as described previously, IL-8, IL-12, and TNF $\alpha$  concentrations of the collected supernatants were analysed by Luminex assay.

#### 4.9 | Statistical analysis

Data obtained from flow cytometry was analysed using FlowJo 10 (FlowJo LLC). Statistical analysis of data was performed using GraphPad Prism 7.02 (GraphPad Software). One-way analysis of variance followed by Dunnett's or Tukey's test or two-way analysis of variance followed by Tukey's test were performed. Only significant differences between samples (p < .05) were indicated on graphs.

#### ACKNOWLEDGEMENTS

The authors would like to thank Laboratory of Translational Immunology, MultiPlex Core Facility (UMC Utrecht, The Netherlands) for performing Luminex assay, Alex McCarthy, Kok van Kessel, Carla de Haas and Piet Aerts (UMC Utrecht, The Netherlands), and Frederike Kisters and Mareike Popp (University of Tübingen, Germany) for scientific expertise and assistance during laboratory work.

This work was supported by the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 675106 coordinated by Dr. Fabio Bagnoli, GSK Vaccines S.r.l., Siena, Italy.

#### AUTHOR CONTRIBUTIONS

M. E. M., R. v. D., A. P., and N. M. v. S. planned the experiments. M. E. M., A.H. and D. G. performed the experiments and analysed the data. M. E. M. performed statistical analysis. G. X. analysed *Staphylococcus lugdunensis* genome, D. G. did molecular cloning, SaPI transfer assay and WTA isolation, and PAGE analysis, and A. P. provided the bacterial strains. M. E. M. and N. M. v. S. wrote the manuscript. All authors revised and approved the manuscript.

#### CONFLICT OF INTERESTS

M. E. M is a PhD fellow and is enrolled in the Infection and Immunity PhD programme, part of the Graduate school of Life Sciences at the University of Utrecht and participated in a postgraduate studentship programme at Glaxo Smith Kline (GSK).

#### ORCID

Nina M. van Sorge D https://orcid.org/0000-0002-2695-5863

#### REFERENCES

- Brown, G. D., Willment, J. A., & Whitehead, L. (2018). C-type lectins in immunity and homeostasis. *Nature Reviews. Immunology*, 18, 374–389. https://doi.org/10.1038/s41577-018-0004-8
- Brown, S., Xia, G., Luhachack, L. G., Campbell, J., Meredith, T. C., Chen, C., ... Walker, S. (2012). Methicillin resistance in *Staphylococcus aureus* requires glycosylated wall teichoic acids. *Proceedings of the National Academy of Sciences of the United States of America*, 109, 18909–18914. https://doi.org/10.1073/pnas.1209126109
- Bruckner, R. (1992). A series of shuttle vectors for Bacillus subtilis and Escherichia coli. Gene, 122, 187–192. https://doi.org/10.1016/0378-1119(92)90048-T
- Endl, J., Seidl, H. P., Fiedler, F., & Schleifer, K. H. (1983). Chemical composition and structure of cell wall teichoic acids of staphylococci. Archives of Microbiology, 135, 215–223. https://doi.org/10.1007/BF00414483
- Eriksen, N. H., Espersen, F., Rosdahl, V. T., & Jensen, K. (1995). Carriage of Staphylococcus aureus among 104 healthy persons during a 19-month period. Epidemiology and Infection, 115, 51–60. https://doi.org/ 10.1017/S0950268800058118
- Gerlach, D., Guo, Y., De Castro, C., Kim, S. H., Schlatterer, K., Xu, F. F., ... Sirisarn, W. (2018). Methicillin-resistant *Staphylococcus aureus* alters cell wall glycosylation to evade immunity. *Nature*, *563*, 705–709. https://doi. org/10.1038/s41586-018-0730-x
- Heger, L., Balk, S., Luhr, J. J., Heidkamp, G. F., Lehmann, C. H. K., Hatscher, L., ... Cesnjevar, R. (2018). CLEC10A is a specific marker for human CD1c(+) dendritic cells and enhances their toll-like receptor 7/8-induced cytokine secretion. *Frontiers in Immunology*, 9, 744. https://doi.org/ 10.3389/fimmu.2018.00744
- Holtfreter, S., Grumann, D., Schmudde, M., Nguyen, H. T., Eichler, P., Strommenger, B., ... Witte, W. (2007). Clonal distribution of superantigen genes in clinical *Staphylococcus aureus* isolates. *Journal of Clinical Microbiology*, 45, 2669–2680. https://doi.org/10.1128/JCM.00204-07
- Kluytmans, J., van Belkum, A., & Verbrugh, H. (1997). Nasal carriage of Staphylococcus aureus: Epidemiology, underlying mechanisms, and associated risks. Clinical Microbiology Reviews, 10, 505–520. https://doi.org/ 10.1128/CMR.10.3.505
- Kurokawa, K., Jung, D. J., An, J. H., Fuchs, K., Jeon, Y. J., Kim, N. H., ... Lee, B. L. (2013). Glycoepitopes of staphylococcal wall teichoic acid govern complement-mediated opsonophagocytosis via human serum antibody and mannose-binding lectin. J Biol Chem, 288(43), 30956–30968.
- Lakhundi, S., & Zhang, K. (2018). Methicillin-Resistant Staphylococcus aureus: Molecular Characterization, Evolution, and Epidemiology. Clinical

### 10 of 10 | WILEY

Microbiology Reviews, 31, e00020-18. https://doi.org/10.1128/ CMR.00020-18

- Lee, J. H., Kim, N. H., Winstel, V., Kurokawa, K., Larsen, J., An, J. H., ... Lee, B. L. (2015). Surface glycopolymers are crucial for in vitro anti-wall teichoic acid IgG-mediated complement activation and opsonophagocytosis of *Staphylococcus aureus*. *Infection and Immunity*, 83, 4247–4255. https:// doi.org/10.1128/IAI.00767-15
- Maalej, M. M., Forgione, R. E., Marchetti, R., Bulteau, F. B., Thepaut, M. T., Lanzetta, R., ... Silipo, A. (2019). The human macrophage galactose-type lectin, MGL, recognizes the outer core of E. coli lipooligosaccharide. *Chembiochem: a European journal of chemical biology*. https://doi.org/ 10.1002/cbic.201900087
- Park, K. H., Kurokawa, K., Zheng, L., Jung, D. J., Tateishi, K., Jin, J. O., ... Lee, B. L. (2010). Human serum mannose-binding lectin senses wall teichoic acid Glycopolymer of Staphylococcus aureus, which is restricted in infancy. J Biol Chem, 285(35), 27167–27175.
- Pozzi, C., Olaniyi, R., Liljeroos, L., Galgani, I., Rappuoli, R., & Bagnoli, F. (2017). Vaccines for Staphylococcus aureus and target populations. Current Topics in Microbiology and Immunology, 409, 491–528. https://doi.org/ 10.1007/82\_2016\_54
- Sallusto, F., & Lanzavecchia, A. (1994). Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. The Journal of Experimental Medicine, 179, 1109–1118. https://doi.org/10.1084/jem.179.4.1109
- Schutz, F., & Hackstein, H. (2014). Identification of novel dendritic cell subset markers in human blood. *Biochemical and Biophysical Research Communications*, 443, 453–457. https://doi.org/10.1016/j.bbrc.2013.11.112
- Singh, S. K., Streng-Ouwehand, I., Litjens, M., Weelij, D. R., Garcia-Vallejo, J. J., van Vliet, S. J., Saeland, E., ... van Kooyk, Y. (2009). Characterization of murine MGL1 and MGL2 C-type lectins: distinct glycan specificities and tumor binding properties. *Mol Immunol*, 46(6), 1240–1249.
- Suzuki, N., Yamamoto, K., Toyoshima, S., Osawa, T., & Irimura, T. (1996). Molecular cloning and expression of cDNA encoding human macrophage C-type lectin. Its unique carbohydrate binding specificity for Tn antigen. *Journal of Immunology*, 156, 128–135.
- Swoboda, J. G., Campbell, J., Meredith, T. C., & Walker, S. (2010). Wall teichoic acid function, biosynthesis, and inhibition. *Chembiochem: a European journal of chemical biology*, 11, 35–45.
- Tanaka, J., Gleinich, A. S., Zhang, Q., Whitfield, R., Kempe, K., Haddleton, D. M., ... Wilson, P. (2017). Specific and differential binding of Nacetylgalactosamine glycopolymers to the human macrophage galactose lectin and asialoglycoprotein receptor. *Biomacromolecules*, 18, 1624–1633. https://doi.org/10.1021/acs.biomac.7b00228
- van Dalen, R., De La Cruz Diaz, J. S., Rumpret, M., Fuchsberger, F. F., van Teijlingen, N. H., Hanske, J., van Sorge, N. M. (2019). Langerhans Cells Sense Staphylococcus aureus Wall Teichoic Acid through Langerin To Induce Inflammatory Responses. *mBio*, 10(3).
- van Liempt, E., van Vliet, S. J., Engering, A., Garcia Vallejo, J. J., Bank, C. M., Sanchez-Hernandez, M., ... van Die, I. (2007). Schistosoma mansoni soluble egg antigens are internalized by human dendritic cells through multiple C-type lectins and suppress TLR-induced dendritic cell activation. *Molecular Immunology*, 44, 2605–2615. https://doi.org/10.1016/j. molimm.2006.12.012
- van Sorge, N. M., Bleumink, N. M., van Vliet, S. J., Saeland, E., van der Pol, W. L., van Kooyk, Y., & van Putten, J. P. (2009). N-glycosylated proteins and distinct lipooligosaccharide glycoforms of *Campylobacter jejuni* target the human C-type lectin receptor MGL. *Cellular Microbiology*, 11, 1768–1781. https://doi.org/10.1111/j.1462-5822.2009.01370.x
- van Vliet, S. J., Bay, S., Vuist, I. M., Kalay, H., Garcia-Vallejo, J. J., Leclerc, C., & van Kooyk, Y. (2013). MGL signaling augments TLR2-mediated

responses for enhanced IL-10 and TNF-α secretion. *Journal of Leukocyte Biology*, 94, 315–323. https://doi.org/10.1189/jlb.1012520

- van Vliet, S. J., Gringhuis, S. I., Geijtenbeek, T. B., & van Kooyk, Y. (2006). Regulation of effector T cells by antigen-presenting cells via interaction of the C-type lectin MGL with CD45. *Nature Immunology*, 7, 1200–1208. https://doi.org/10.1038/ni1390
- van Vliet, S. J., Paessens, L. C., Broks-van den Berg, V. C., Geijtenbeek, T. B., & van Kooyk, Y. (2008). The C-type lectin macrophage galactose-type lectin impedes migration of immature APCs. *Journal of Immunology*, 181, 3148–3155. https://doi.org/10.4049/jimmunol.181.5.3148
- van Vliet, S. J., Steeghs, L., Bruijns, S. C., Vaezirad, M. M., Blok, C. S., Busto, J. A., ... van Kooyk, Y. (2009). Variation of *Neisseria gonorrhoeae* lipooligosaccharide directs dendritic cell-induced T helper responses. *PLoS Pathogens*, *5*, e1000625. https://doi.org/10.1371/journal. ppat.1000625
- van Vliet, S. J., van Liempt, E., Saeland, E., Aarnoudse, C. A., Appelmelk, B., Irimura, T., ... van Kooyk, Y. (2005). Carbohydrate profiling reveals a distinctive role for the C-type lectin MGL in the recognition of helminth parasites and tumor antigens by dendritic cells. *International Immunology*, 17, 661–669. https://doi.org/10.1093/intimm/dxh246
- Weidenmaier, C., & Lee, J. C. (2016). Structure and function of surface polysaccharides of *Staphylococcus aureus*. Current Topics in Microbiology and Immunology, 409, 57.
- Weidenmaier, C., & Peschel, A. (2008). Teichoic acids and related cell-wall glycopolymers in Gram-positive physiology and host interactions. *Nature Reviews. Microbiology*, *6*, 276–287. https://doi.org/10.1038/ nrmicro1861
- Weigel, L. M., Clewell, D. B., Gill, S. R., Clark, N. C., McDougal, L. K., Flannagan, S. E., ... Tenover, F. C. (2003). Genetic analysis of a highlevel b\_k;vancomycin-resistant isolate of *Staphylococcus aureus. Science*, 302, 1569–1571. https://doi.org/10.1126/science.1090956
- Wertheim, H. F., Melles, D. C., Vos, M. C., van Leeuwen, W., van Belkum, A., Verbrugh, H. A., & Nouwen, J. L. (2005). The role of nasal carriage in *Staphylococcus aureus* infections. *The Lancet Infectious Diseases*, *5*, 751–762. https://doi.org/10.1016/S1473-3099(05)70295-4
- Winstel, V., Liang, C., Sanchez-Carballo, P., Steglich, M., Munar, M., Broker, B. M., ... Peschel, A. (2013). Wall teichoic acid structure governs horizontal gene transfer between major bacterial pathogens. *Nature Communications*, 4, 2345. https://doi.org/10.1038/ncomms3345
- Winstel, V., Sanchez-Carballo, P., Holst, O., Xia, G., & Peschel, A. (2014). Biosynthesis of the unique wall teichoic acid of *Staphylococcus aureus* lineage ST395. *MBio*, 5, e00869.
- Xia, G., Maier, L., Sanchez-Carballo, P., Li, M., Otto, M., Holst, O., & Peschel, A. (2010). Glycosylation of wall teichoic acid in *Staphylococcus aureus* by TarM. *The Journal of Biological Chemistry*, 285, 13405–13415. https:// doi.org/10.1074/jbc.M109.096172

#### SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Mnich ME, van Dalen R, Gerlach D, et al. The C-type lectin receptor MGL senses *N*acetylgalactosamine on the unique *Staphylococcus aureus* ST395 wall teichoic acid. *Cellular Microbiology*. 2019;21: e13072. https://doi.org/10.1111/cmi.13072